デフォルト表紙
市場調査レポート
商品コード
1001335

抗凝固拮抗薬の世界市場:業界分析、市場規模・シェア・成長率・動向・予測(2020年~2027年)

Global Anticoagulant Reversal Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends And Forecast 2020 to 2027

出版日: | 発行: Value Market Research | ページ情報: 英文 136 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.57円
抗凝固拮抗薬の世界市場:業界分析、市場規模・シェア・成長率・動向・予測(2020年~2027年)
出版日: 2021年04月01日
発行: Value Market Research
ページ情報: 英文 136 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の抗凝固拮抗薬の市場規模は、2021年から2027年の予測期間中に大幅に拡大すると予測されています。

当レポートでは、世界の抗凝固拮抗薬市場について分析し、業界の概要や市場の基本構造、主な市場成長・抑制要因、市場規模の動向見通し、 Covid-19発生の影響分析、セグメント別および地域別の詳細動向、市場競合情勢、主要企業のプロファイルの情報等を提供しております。

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 業界分析

  • イントロダクション-市場力学
  • 市場成長要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場の魅力分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
  • 潜在的なバイヤーのリスト
  • 販売チャネル

第5章 COVID-19アウトブレイクの影響分析

  • Covid-19アウトブレイクの影響分析
  • 生産、輸入、輸出および需要別COVID-19影響分析
  • 市場:プレ / ポストCOVID-19
  • コロナウイルス(COVID-19)の流行の推定影響
  • COVID-19:ミクロおよびマクロ因子分析

第6章 製品タイプ別市場分析

  • 製品タイプの概要
  • 実績データと予測データ
  • 製品タイプの分析
  • 地域別のプロトロンビン複合体濃縮製剤市場
  • 地域別のフィトナジオン市場
  • 地域別のアンデキサネットアルファ市場
  • 地域別のイダルシズマブ市場
  • 地域別のプロタミン市場
  • 地域別のその他の市場

第7章 流通チャネル別市場分析

  • 流通チャネル別概要
  • 実績データと予測データ
  • 流通チャネル別分析
  • 地域別の病院薬局市場
  • 地域別の小売薬局市場
  • 地域別のオンライン薬局市場

第8章 地域別分析

  • 地域の見通し
  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 企業競合情勢

  • 市場競争
  • パートナーシップ/コラボレーション/契約
  • 合併・買収
  • 新製品の発売
  • その他の開発

第10章 企業プロファイル

  • 企業シェア分析
  • 市場集中度
  • Portola Pharmaceuticals
  • CSL Behring
  • Boehringer Ingelheim
  • Octapharma AG
  • AMAG Pharmaceuticals, Inc.
  • Dr. Reddy's Laboratories
  • Pfizer, Inc.
  • Fresenius Kabi AG
  • Bausch Health Companies Inc.
  • Octapharma AG, SGPharma Pvt. Ltd.
  • Alps Pharmaceutical Ind. Co. Ltd.

注)企業のプロファイリングでは、財務の詳細と最新動向は入手状況によります。民間企業の場合はカバーされない場合があります

図表

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • COVID-19 Impact Analysis by Production, Import, Export and Demand
  • Pre V/S Post COVID-19
  • Estimated Impact Of The Coronavirus (Covid-19) Epidemic
  • COVID-19: Micro and Macro Factor Analysis
  • Analysis by Product Type (USD MN)
  • Prothrombin Complex Concentrates Market by Geography (USD MN)
  • Phytonadione Market by Geography (USD MN)
  • Andexanet Alfa Market by Geography (USD MN)
  • Idarucizumab Market by Geography (USD MN)
  • Protamine Market by Geography (USD MN)
  • Others Market by Geography (USD MN)
  • Analysis Market by Distribution Channel (USD MN)
  • Hospital Pharmacy Market by Geography (USD MN)
  • Retail Pharmacy Market by Geography (USD MN)
  • Online Pharmacy Market by Geography (USD MN)
  • Global Anticoagulant Reversal Drugs Market by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisiton

LIST OF FIGURES

  • Research Scope of Anticoagulant Reversal Drugs Report
  • Market Research Process
  • Market Research Methodology
  • Global Anticoagulant Reversal Drugs Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Product Type
  • Market Attractiveness Analysis by Distribution Channel
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Product Type (USD MN)
  • Prothrombin Complex Concentrates Market by Geography (USD MN)
  • Phytonadione Market by Geography (USD MN)
  • Andexanet Alfa Market by Geography (USD MN)
  • Idarucizumab Market by Geography (USD MN)
  • Protamine Market by Geography (USD MN)
  • Others Market by Geography (USD MN)
  • Global Market Analysis by Distribution Channel (USD MN)
  • Hospital Pharmacy Market by Geography (USD MN)
  • Retail Pharmacy Market by Geography (USD MN)
  • Online Pharmacy Market by Geography (USD MN)
  • Global Market by Revenue
  • North America Market by Revenue
  • Europe Market by Revenue
  • Asia Pacific Market by Revenue
  • Latin America Market by Revenue
  • Middle East & Africa Market by Revenue
  • Recent Development in Industry
  • Company Market Share Analysis, 2020

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次

Value Market Research's latest report on the Global Anticoagulant Reversal Drugs Market identified a significant growth in the industry over the last few years and anticipates it to grow considerably within the forecast period of 2021-2027.

The global anticoagulant reversal drugs market report provides a complete evaluation of the market for the forecast period. The report consists of various segments as well as an analysis of the factors playing a significant role in the market. The factors include the drivers, restraints, challenges and opportunities and the impact of these factors on the market has been provided in the report. The drivers and restraints are classified as intrinsic factors while the opportunities and challenges are classified as extrinsic factors of the market. The global anticoagulant reversal drugs market study provides an insight on the developments of the market in terms of revenue throughout the specified period.

This report provides a complete analysis for the global anticoagulant reversal drugs market. An in-depth secondary research, primary interviews and in-house expert reviews are responsible for providing the market estimates for the global anticoagulant reversal drugs market. These market estimates have been put together by studying the impact of different social, political and economic factors along with the current market dynamics that are affecting the global anticoagulant reversal drugs market growth.

The report begins with the market overview, followed by a crisp executive summary. The Porter's Five Forces analysis covered in this study will assist in understanding the five forces namely buyers bargaining power, suppliers bargaining power, threat of new entrants, the threat of substitutes and the degree of competition in the global anticoagulant reversal drugs market. It also helps to explain the various participants such as system integrators, intermediaries and end users within the market. The report by Value Market Research also focuses on the competitive landscape of the global anticoagulant reversal drugs market.

The market analysis involves a section exclusively to list the major players of the global anticoagulant reversal drugs market wherein our analysts provide an insight into the financial statements of all the key players along with its key development product. The company profile section in the report also provides a business overview and financial information. The companies provided in this section can be customized as per the client's requirement.

The Anticoagulant Reversal Drugs Market Report Segments the market as below-

By Product Type

Prothrombin Complex Concentrates

Phytonadione

Andexanet Alfa

Idarucizumab

Protamine

Others

By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . ANTICOAGULANT REVERSAL DRUGS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 By Product Type
    • 3.7.2 By Distribution Channel
    • 3.7.3 By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

  • 5.1. Impact Analysis of Covid-19 Outbreak
    • 5.1.1. Direct Impact on Production
    • 5.1.2. Supply Chain and Market Disruption
    • 5.1.3. Financial Impact on Firms and Financial Markets
  • 5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
  • 5.3. Market: Pre V/S Post COVID-19
  • 5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic
  • 5.5. COVID-19: Micro and Macro Factor Analysis

6 . GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET ANALYSIS BY PRODUCT TYPE

  • 6.1 Overview by Product Type
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Product Type
  • 6.4 Prothrombin Complex Concentrates Market by Regions
  • 6.6 Phytonadione Market by Regions
  • 6.5 Andexanet Alfa Market by Regions
  • 6.7 Idarucizumab Market by Regions
  • 6.8 Protamine Market by Regions
  • 6.9 Others Market by Regions

7 . GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 7.1 Overview by Distribution Channel
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Distribution Channel
  • 7.4 Hospital Pharmacy Market by Regions
  • 7.5 Retail Pharmacy Market by Regions
  • 7.6 Online Pharmacy Market by Regions

8 . GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America
    • 8.3.1. Overview, Historic and Forecast Data
    • 8.3.2. North America By Segment
    • 8.3.3. North America By Country
    • 8.3.4. United State
    • 8.3.5. Canada
    • 8.3.6. Mexico
  • 8.4. Europe
    • 8.4.1. Overview, Historic and Forecast Data
    • 8.4.2. Europe by Segment
    • 8.4.3. Europe by Country
    • 8.4.4. United Kingdom
    • 8.4.5. France
    • 8.4.6. Germany
    • 8.4.7. Italy
    • 8.4.8. Russia
    • 8.4.9. Rest Of Europe
  • 8.5. Asia Pacific
    • 8.5.1. Overview, Historic and Forecast Data
    • 8.5.2. Asia Pacific by Segment
    • 8.5.3. Asia Pacific by Country
    • 8.5.4. China
    • 8.5.5. India
    • 8.5.6. Japan
    • 8.5.7. South Korea
    • 8.5.8. Australia
    • 8.5.9. Rest Of Asia Pacific
  • 8.6. Latin America
    • 8.6.1. Overview, Historic and Forecast Data
    • 8.6.2. Latin America by Segment
    • 8.6.3. Latin America by Country
    • 8.6.4. Brazil
    • 8.6.5. Argentina
    • 8.6.6. Peru
    • 8.6.7. Chile
    • 8.6.8. Rest of Latin America
  • 8.7. Middle East & Africa
    • 8.7.1. Overview, Historic and Forecast Data
    • 8.7.2. Middle East & Africa by Segment
    • 8.7.3. Middle East & Africa by Country
    • 8.7.4. Saudi Arabia
    • 8.7.5. UAE
    • 8.7.6. Israel
    • 8.7.7. South Africa
    • 8.7.8. Rest Of Middle East And Africa

9 . COMPETITIVE LANDSCAPE OF THE ANTICOAGULANT REVERSAL DRUGS COMPANIES

  • 9.1. Anticoagulant Reversal Drugs Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10 . COMPANY PROFILES OF ANTICOAGULANT REVERSAL DRUGS INDUSTRY

  • 10.1. Company Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Portola Pharmaceuticals
    • 10.3.1. Company Overview
    • 10.3.2. Financials
    • 10.3.3. Products
    • 10.3.4. Recent Developments
  • 10.4. CSL Behring
    • 10.4.1. Company Overview
    • 10.4.2. Financials
    • 10.4.3. Products
    • 10.4.4. Recent Developments
  • 10.5. Boehringer Ingelheim
    • 10.5.1. Company Overview
    • 10.5.2. Financials
    • 10.5.3. Products
    • 10.5.4. Recent Developments
  • 10.6. Octapharma AG
    • 10.6.1. Company Overview
    • 10.6.2. Financials
    • 10.6.3. Products
    • 10.6.4. Recent Developments
  • 10.7. AMAG Pharmaceuticals, Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Financials
    • 10.7.3. Products
    • 10.7.4. Recent Developments
  • 10.8. Dr. Reddy's Laboratories
    • 10.8.1. Company Overview
    • 10.8.2. Financials
    • 10.8.3. Products
    • 10.8.4. Recent Developments
  • 10.9. Pfizer, Inc.
    • 10.9.1. Company Overview
    • 10.9.2. Financials
    • 10.9.3. Products
    • 10.9.4. Recent Developments
  • 10.10. Fresenius Kabi AG
    • 10.10.1. Company Overview
    • 10.10.2. Financials
    • 10.10.3. Products
    • 10.10.4. Recent Developments
  • 10.11. Bausch Health Companies Inc.
    • 10.11.1. Company Overview
    • 10.11.2. Financials
    • 10.11.3. Products
    • 10.11.4. Recent Developments
  • 10.12. Octapharma AG, SGPharma Pvt. Ltd.
    • 10.12.1. Company Overview
    • 10.12.2. Financials
    • 10.12.3. Products
    • 10.12.4. Recent Developments
  • 10.13. Alps Pharmaceutical Ind. Co. Ltd.
    • 10.13.1. Company Overview
    • 10.13.2. Financials
    • 10.13.3. Products
    • 10.13.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies